Literature DB >> 17197831

K65R development among subtype C HIV-1-infected patients in tenofovir DF clinical trials.

Michael D Miller, Nicolas Margot, Damian McColl, Andrew K Cheng.   

Abstract

Entities:  

Mesh：

Substances：

Year:  2007        PMID： 17197831     DOI： 10.1097/QAD.0b013e32801199ee

Source DB:  PubMed          Journal:  AIDS        ISSN： 0269-9370            Impact factor:   4.177


× No keyword cloud information.
  13 in total

1.  Comparative analysis of drug resistance among B and the most prevalent non-B HIV type 1 subtypes (C, F, and CRF02_AG) in Italy.

Authors:  Maria Mercedes Santoro; Claudia Alteri; Luigi Ronga; Philippe Flandre; Lavinia Fabeni; Fabio Mercurio; Roberta D'Arrigo; Caterina Gori; Guido Palamara; Ada Bertoli; Federica Forbici; Romina Salpini; Evangelo Boumis; Valerio Tozzi; Ubaldo Visco-Comandini; Mauro Zaccarelli; Margriet Van Houtte; Theresa Pattery; Pasquale Narciso; Andrea Antinori; Francesca Ceccherini-Silberstein; Carlo Federico Perno
Journal:  AIDS Res Hum Retroviruses       Date:  2012-04-18       Impact factor: 2.205

Review 2.  The challenge of HIV-1 subtype diversity.

Authors:  Barbara S Taylor; Magdalena E Sobieszczyk; Francine E McCutchan; Scott M Hammer
Journal:  N Engl J Med       Date:  2008-04-10       Impact factor: 91.245

3.  HIV-1 subtype is an independent predictor of reverse transcriptase mutation K65R in HIV-1 patients treated with combination antiretroviral therapy including tenofovir.

Authors:  K Theys; J Vercauteren; J Snoeck; M Zazzi; R J Camacho; C Torti; E Schülter; B Clotet; A Sönnerborg; A De Luca; Z Grossman; D Struck; A-M Vandamme; A B Abecasis
Journal:  Antimicrob Agents Chemother       Date:  2012-11-26       Impact factor: 5.191

4.  The K65R mutation in HIV-1 reverse transcriptase: genetic barriers, resistance profile and clinical implications.

Authors:  Bluma G Brenner; Dimitrios Coutsinos
Journal:  HIV Ther       Date:  2009-11-01

5.  Template usage is responsible for the preferential acquisition of the K65R reverse transcriptase mutation in subtype C variants of human immunodeficiency virus type 1.

Authors:  Dimitrios Coutsinos; Cédric F Invernizzi; Hongtao Xu; Daniela Moisi; Maureen Oliveira; Bluma G Brenner; Mark A Wainberg
Journal:  J Virol       Date:  2008-12-10       Impact factor: 5.103

6.  Cost-effectiveness of tenofovir instead of zidovudine for use in first-line antiretroviral therapy in settings without virological monitoring.

Authors:  Viktor von Wyl; Valentina Cambiano; Michael R Jordan; Silvia Bertagnolio; Alec Miners; Deenan Pillay; Jens Lundgren; Andrew N Phillips
Journal:  PLoS One       Date:  2012-08-08       Impact factor: 3.240

7.  Clinical and genotypic findings in HIV-infected patients with the K65R mutation failing first-line antiretroviral therapy in Nigeria.

Authors:  Claudia A Hawkins; Beth Chaplin; John Idoko; Ernest Ekong; Isaac Adewole; Wadzani Gashau; Robert L Murphy; Phyllis Kanki
Journal:  J Acquir Immune Defic Syndr       Date:  2009-10-01       Impact factor: 3.731

8.  Targeting of the purine biosynthesis host cell pathway enhances the activity of tenofovir against sensitive and drug-resistant HIV-1.

Authors:  Alonso Heredia; Charles E Davis; Marvin S Reitz; Nhut M Le; Mark A Wainberg; James S Foulke; Lai-Xi Wang; Robert R Redfield
Journal:  J Infect Dis       Date:  2013-08-06       Impact factor: 5.226

9.  Reverse transcriptase inhibitors as potential colorectal microbicides.

Authors:  Carolina Herrera; Martin Cranage; Ian McGowan; Peter Anton; Robin J Shattock
Journal:  Antimicrob Agents Chemother       Date:  2009-03-02       Impact factor: 5.191

10.  Factors influencing the emergence and spread of HIV drug resistance arising from rollout of antiretroviral pre-exposure prophylaxis (PrEP).

Authors:  Ume L Abbas; Gregory Hood; Arthur W Wetzel; John W Mellors
Journal:  PLoS One       Date:  2011-04-15       Impact factor: 3.240
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.